BeiGene Ltd. ADR (BGNE): Price and Financial Metrics

BeiGene Ltd. ADR (BGNE): $204.21

1.57 (+0.77%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add BGNE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#94 of 328

in industry

BGNE Price/Volume Stats

Current price $204.21 52-week high $248.16
Prev. close $202.64 52-week low $126.97
Day low $202.90 Volume 463,000
Day high $209.05 Avg. volume 264,008
50-day MA $211.64 Dividend yield N/A
200-day MA $171.70 Market Cap 19.88B

BGNE Stock Price Chart Interactive Chart >


BeiGene Ltd. ADR (BGNE) Company Bio


BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)


BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

BGNE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!